FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx today announced the launch of its in-silico panel program which is an extension of its Genomic Unity™ whole genome sequencing (WGS)-based testing service. Available to clinicians since 2017, Genomic Unity™ has been instrumental in resolving many complex patient cases. It pairs the patient’s complete DNA sequence with proprietary data analysis algorithms to detect genome-wide small sequence changes, structural variants, mitochondrial variants and tandem repeat expansions - all within a single assay.
Introduction of the in-silico panel program will provide greater ordering flexibility for clinicians working with narrow reimbursement policies. They will now have the option to order targeted in-silico analyses directed at a subset of genes within multiple therapeutic areas including movement disorders, mitochondrial disorders, epilepsy, intellectual disability and neurology. All analyses provide the option to reflex up to the full Genomic Unity™ test.
Variantyx Chief Director of Clinical Genomics Christine Stanley, PhD, FACMG states: “When you only have one chance to identify the molecular cause of a patient’s symptoms, it’s so important to be able to select the most comprehensive test available. The new in-silico panel program supports the targeted testing approach preferred by many payors, while keeping open the possibility to later analyze the full DNA sequence through the reflex option.”
The company will be presenting its Genomic Unity™ testing program at the National Society of Genetic Counselors (NSGC) annual conference November 5-8 in Salt Lake City, Utah.
About Variantyx: Variantyx is a CLIA/CAP laboratory providing Genomic Unity™, a whole genome sequencing (WGS)-based testing program for diagnosis of rare inherited disorders. Its single method approach to comprehensive genetic testing identifies multiple variant types within a single patient sample to provide a unified clinical report. For more information, please visit www.variantyx.com.